Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 24;9(10):2160.
doi: 10.3390/cells9102160.

Tuberculosis-Associated MicroRNAs: From Pathogenesis to Disease Biomarkers

Alessandro Sinigaglia  1 , Elektra Peta  1 , Silvia Riccetti  1 , Seshasailam Venkateswaran  2 , Riccardo Manganelli  1 , Luisa Barzon  1
Affiliations
Review

Tuberculosis-Associated MicroRNAs: From Pathogenesis to Disease Biomarkers

Alessandro Sinigaglia et al. Cells. .

Abstract

Tuberculosis (TB) caused by Mycobacterium tuberculosis is one of the most lethal infectious diseases with estimates of approximately 1.4 million human deaths in 2018. M. tuberculosis has a well-established ability to circumvent the host immune system to ensure its intracellular survival and persistence in the host. Mechanisms include subversion of expression of key microRNAs (miRNAs) involved in the regulation of host innate and adaptive immune response against M. tuberculosis. Several studies have reported differential expression of miRNAs during active TB and latent tuberculosis infection (LTBI), suggesting their potential use as biomarkers of disease progression and response to anti-TB therapy. This review focused on the miRNAs involved in TB pathogenesis and on the mechanism through which miRNAs induced during TB modulate cell antimicrobial responses. An attentive study of the recent literature identifies a group of miRNAs, which are differentially expressed in active TB vs. LTBI or vs. treated TB and can be proposed as candidate biomarkers.

Keywords: apoptosis; autophagy; biomarker; diagnosis; disease progression; innate immunity; latent infection; microRNA; pathogenesis; response to therapy; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Tuberculosis pathogenesis and disease progression. Mycobacterium tuberculosis infection initiates with inhalation of droplets that carry bacteria and their uptake by alveolar macrophages. Innate immune responses characterize the initial phase of infection, with recruitment of inflammatory cells in the lung. Bacterial dissemination to the draining lymph node leads to T cell priming and expansion of antigen-specific T cells. Recruitment of activated macrophages, neutrophils, T cells, and B cells in the lung leads to granuloma formation, which contains M. tuberculosis in a latent status. However, in about 10% of infected individuals, M. tuberculosis escapes immune control and granulomas are disrupted, with release of infectious bacteria.
Figure 2
Figure 2
Graphical representation of miRNA regulation of host immune responses against M. tuberculosis infection. MicroRNAs that are up-regulated or down-regulated during M. tuberculosis infection are indicated with red and green arrows, respectively.
Figure 3
Figure 3
Graphical representation of circulating miRNAs, which are significantly up-regulated (red arrow) or down-regulated (green arrow) in subjects with latent tuberculosis (TB) infection, active TB, or who responded to anti-TB therapy, and have been proposed as candidate biomarkers.
See this image and copyright information in PMC

References

    1. Dye C., Williams B.G. The population dynamics and control of tuberculosis. Science. 2010;328:856–861. doi: 10.1126/science.1185449. - DOI - PubMed
    1. WHO . Global Tuberculosis Report 2019. World Health Organization; Geneva, Switzerland: 2019. Licence: CC BY-NC-SA 3.0 IGO.
    1. Pai M., Behr M.A., Dowdy D., Dheda K., Divangahi M., Boehme C.C., Ginsberg A., Swaminathan S., Spigelman M., Getahun H., et al. Tuberculosis. Nat. Rev. Dis. Primers. 2016;2:16076. doi: 10.1038/nrdp.2016.76. - DOI - PubMed
    1. Simmons J.D., Stein C.M., Seshadri C., Campo M., Alter G., Fortune S., Schurr E., Wallis R.S., Churchyard G., Mayanja-Kizza H., et al. Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. Nat. Immun. 1996;64:683–690. doi: 10.1038/s41577-018-0025-3. - DOI - PMC - PubMed
    1. Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin. Microbiol. Rev. 2003;16:463–496. doi: 10.1128/CMR.16.3.463-496.2003. - DOI - PMC - PubMed

Publication types